HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 294/1/C126    most recent 00464.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, D. Articles by McDonough, A. A. Search for Related Content PubMed PubMed Citation Articles by Zheng, D. Articles by McDonough, A. A.

MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS

AMPK activation with AICAR provokes an acute fall in plasma [K⁺]

¹Department of Physiology and Biophysics, University of Southern California Keck School of Medicine, ²Department of Anatomy-Physiology and Lipid Research Unit, Laval University Hospital Research Centre, Quebec, Canada

Submitted 4 October 2007 ; accepted in final form 12 November 2007

AMP-activated protein kinase (AMPK), activated by an increase in intracellular AMP-to-ATP ratio, stimulates pathways that can restore ATP levels. We tested the hypothesis that AMPK activation influences extracellular fluid (ECF) K⁺ homeostasis. In conscious rats, AMPK was activated with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) infusion: 38.4 mg/kg bolus then 4 mg·kg^–1·min^–1 infusion. Plasma [K⁺] and [glucose] both dropped at 1 h of AICAR infusion and [K⁺] dropped to 3.3 ± 0.04 mM by 3 h, linearly related to the increase in muscle AMPK phosphorylation. AICAR treatment did not increase urinary K⁺ excretion. AICAR lowered [K⁺] whether plasma [K⁺] was chronically elevated or lowered. The K⁺ infusion rate needed to maintain baseline plasma [K⁺] reached 15.7 ± 1.3 µmol K⁺·kg^–1·min^–1 between 120 and 180 min AICAR infusion. In mice expressing a dominant inhibitory form of AMPK in the muscle (Tg-KD1), baseline [K⁺] was not different from controls (4.2 ± 0.1 mM), but the fall in plasma [K⁺] in response to AICAR (0.25 g/kg) was blunted: [K⁺] fell to 3.6 ± 0.1 in controls and to 3.9 ± 0.1 mM in Tg-KD1, suggesting that ECF K⁺ redistributes, at least in part, to muscle ICF. In summary, these findings illustrate that activation of AMPK activity with AICAR provokes a significant fall in plasma [K⁺] and suggest a novel mechanism for redistributing K⁺ from ECF to ICF.

potassium homeostasis; sodium-potassium-ATPase; muscle; urine

This article has been cited by other articles:

				T. Clausen Regulatory role of translocation of Na+-K+ pumps in skeletal muscle: hypothesis or reality? Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E727 - E728. [Full Text] [PDF]

				B. Benziane and A. V. Chibalin Frontiers: Skeletal muscle sodium pump regulation: a translocation paradigm Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E553 - E558. [Abstract] [Full Text] [PDF]